Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-12

Clinical Trial Update: Omalizumab in the Treatment of Peanut Allergy [Phase 2]

View source ↗

Summary

Phase 2 trial results for omalizumab in peanut allergy have been completed, with results posted in July 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xolair (omalizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Food Allergy, Peanut Allergy | Phase 2 | Status: COMPLETED | Results posted: 2017-07-12